• Explore /
  • Poster
  • / Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).

Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).

Abstract Poster

Authors

null

Dong-Sheng Zhang

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China

Dong-Sheng Zhang , Fu-Rong Liu , Yun-Xin Lu , Bing Bai , Yang Zhang , Zhi-Qiang Wang , Yu Liu , Jian-Wen Chen , Feng Wang , Rui-Hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05481476

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 659)

DOI

10.1200/JCO.2024.42.3_suppl.659

Abstract #

659

Poster Bd #

L8

Abstract Disclosures

Similar Posters

First Author: Gang Jin

First Author: Jaime Feliu Batlle

First Author: Zhiwei Chang

First Author: Guang-Hai Dai